Prevention, Combination Therapy, and Comparative Effectiveness Research in Alzheimer's Disease
Funds clinical trials on innovative or repurposed interventions to prevent or reduce Alzheimer’s risk in at-risk human populations, focusing on precision prevention, combination therapies, and comparative effectiveness.
Funder: Alzheimer's Drug Discovery Foundation
Due Dates: September 14, 2026: Letter of Intent deadline
Funding Amounts: Up to $5,000,000 per clinical trial; multi-year projects; milestone-based payments; direct costs only
Summary: Funds clinical research on precision prevention, combination therapies, and comparative effectiveness to reduce Alzheimer’s disease risk, prioritizing innovative or repurposed interventions.
Key Information: Anti-amyloid and cholinesterase inhibitor projects are not eligible; only direct costs are funded.
Description
This grant supports human clinical research aimed at reducing the risk of Alzheimer’s disease or other dementias through precision prevention, combination therapies, and comparative effectiveness studies. The focus is on interventions targeting individuals at risk due to genetic or medical factors or those with biomarker evidence of dementia pathology but not yet symptomatic. Projects may involve novel, repurposed, or repositioned drugs, natural products, supplements, or devices, with particular emphasis on those with strong intellectual property or commercial potential. High-priority mechanisms include metabolic, vascular, inflammatory, neuroprotective, and other biologically relevant pathways. Combination approaches (e.g., drug plus lifestyle intervention) and comparative studies of clinically equivalent drugs are encouraged. Proposals focused solely on lifestyle interventions, anti-amyloid strategies, or cholinesterase inhibitors are not eligible.
